Company
Upstream Bio, Inc. (UPB)
Standardized SEC financial data for Upstream Bio, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0002022626 · NASDAQ · Pharmaceutical Preparations.
Operating margin
-1000.0%
Net margin
-1000.0%
Revenue growth (YoY)
20.4%
Return on equity
-42.2%
Free cash flow
-$133.4M
Current ratio
26.15×
EPS (diluted)
$-2.66
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $2.4M | $2.4M | $2.9M |
| R&D expense | $31.8M | $63.0M | $136.8M |
| SG&A expense | $10.7M | $17.2M |
Balance sheet
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | — | $25.8M | $326.1M | $101.8M |
| Total current assets | — | $117.0M | $479.2M | $351.8M |
Cash flow
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$37.9M | -$59.2M | -$133.3M |
| Capital expenditures | $144K | $511K | $165K |
| Free cash flow | -$38.1M | -$59.7M |
Get UPB data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/UPB/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/UPB/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"